Mark Hensley
Net worth: 118 990 $ as of 2026-05-30
Net worth: 118 990 $ as of 2026-05-30
Mark E.
Hensley currently works at Calliditas Therapeutics AB, as Chairman and Heron Therapeutics, Inc., as Chief Operating Officer from 2025.
Mr. Hensley also formerly worked at Veloxis Pharmaceuticals A, as Chief Commercial Officer from 2018 to 2021.
Mr. Hensley received his undergraduate degree from the University of North Texas.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-05 | 136,770 ( 0.07% ) | 118 990 $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| CALLIDITAS THERAPEUTICS AB | Chairman | - |
| HERON THERAPEUTICS, INC. | Chief Operating Officer | 2025-04-27 |
| Companies | Position | End |
|---|---|---|
| VELOXIS PHARMACEUTICALS A/S | Corporate Officer/Principal | 2020-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Heron Therapeutics, Inc.
Heron Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and commercializes of polymer technologies | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
University of North Texas
University of North Texas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Calliditas Therapeutics AB
Calliditas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
Select your edition
All financial news and data tailored to specific country editions